National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 3 of 10
ATG-GCSF in New Onset Type 1 Diabetes
NCT02215200
Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy
NCT02311348
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
NCT00862433
Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
NCT02404870
Seroprevalence of Hepatitis E in People With an Organ Transplant
NCT02190253
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
NCT02118012
TODAY2 Phase 2 Follow-up
NCT02310724
Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
NCT01950520
Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans
NCT02037295
Study of the Effect of a Very-Low-Carbohydrate Diet on Energy Expenditure
NCT01967563
Evaluation of Sickle Cell Liver Disease
NCT01950429
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
NCT01854827
Identifying Risk for Diabetes and Heart Disease in Women
NCT01809288
Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals
NCT01862796
The Physiology of Fatigue in Patients With Chronic Liver Disease
NCT01867385
Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
NCT01792115
New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C
NCT01888900
Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
NCT01149369
Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix
NCT01812694
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
NCT01773707
Short-term Effects of Leptin in People With Lipodystrophy
NCT01778556
Chronic Cold Exposure and Energy Metabolism in Humans
NCT01730105
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
NCT01369212
Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection
NCT01368497
Evaluation of People With Gastrointestinal Disease
NCT01639924
Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children
NCT01529268
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B
NCT01369199
Energy Expenditure Responses to Different Temperatures
NCT01568671
Lonafarnib for Chronic Hepatitis D
NCT01495585
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
NCT01441154
Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
NCT01581554
Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus
NCT01083108
The Farnesoid X Receptor (FXR) Ligand Obeticholic Acid in NASH Treatment Trial(FLINT)
NCT01265498
TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study
NCT01364350
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men
NCT01294319
Metabolic Effects of Non-Nutritive Sweeteners
NCT01200940
Developing Biomarkers of Dietary Intake
NCT01237093
Water Deprivation Protocol
NCT01224704
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
NCT00947427
Duration of Long-term Immunity After Hepatitis B Virus Immunization
NCT01182311
Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes
NCT01143532
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
NCT01030861
Investigating the Use of Quercetin on Glucose Absorption in Obesity, and Obesity With Type 2 Diabetes
NCT00065676
Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
NCT01144507
Quitting Caffeine for Better Glucose Metabolism
NCT01030796
Partners for Better Health in Adolescent Type 2 Diabetes: The Buddy Study
NCT01007266
Diet-Induced-Obesity Resistant Phenotypes in Humans
NCT00999154
Family Weight Management Study
NCT00851201
Natural History of Autoimmune Diabetes and Its Complications
NCT00896610
The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
NCT00856609
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets.Report a data error.